Roche cobas hrHPV Test Performs Well Across Common Pap Test Platforms
Background
Cervical cancer is a major global health concern, primarily caused by persistent infection with high-risk human papillomavirus (hrHPV). The Papanicolaou (Pap) test is crucial for screening, but its sensitivity can be improved by co-testing with hrHPV detection. Understanding how well the Roche cobas hrHPV test performs on different liquid-based Pap test platforms is essential for optimizing cervical cancer screening strategies.
Results
The Roche cobas hrHPV test demonstrated high diagnostic accuracy on both platforms. For ThinPrep samples, sensitivity was 93.5% and specificity was 82.1% for detecting cervical intraepithelial neoplasia grade 2 or higher (CIN2+). For SurePath samples, sensitivity was 92.8% and specificity was 81.5%, showing comparable performance. > The overall agreement between the Roche cobas hrHPV test and the reference standard was excellent, with a Kappa statistic of 0.78 for ThinPrep and 0.76 for SurePath, indicating strong consistency across platforms. The positive predictive value (PPV) for CIN2+ was 18.2% for ThinPrep and 17.9% for SurePath, while negative predictive value (NPV) was consistently high at 99.5% for both.
Why It Matters
This study provides crucial evidence that the Roche cobas hrHPV test maintains robust performance across the two most common liquid-based Pap test platforms, ThinPrep and SurePath. This consistency is vital for laboratories, ensuring reliable hrHPV detection regardless of the primary liquid-based cytology system used, which can streamline laboratory workflows and improve the efficiency of cervical cancer screening programs. The high negative predictive value further supports its utility in safely extending screening intervals for hrHPV-negative women, potentially reducing unnecessary follow-up procedures.